Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rohit Loomba

Showing results (491-500 of 636) with videos related to

Pageof 64
Sort By:
Gastroenterology|June 19, 2017
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic SteatohepatitisMichael S Middleton, Elhamy R Heba, Catherine A Hooker, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|March 13, 2019
Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance ElastographyCyrielle Caussy, Meera Bhargava, Ida F Villesen, et al.
Contemporary Clinical Trials|March 3, 2021
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosisManal F Abdelmalek, Edgar D Charles, Arun J Sanyal, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Cell Genomics|December 27, 2021
Machine learning enables new insights into genetic contributions to liver fat accumulationMary E Haas, James P Pirruccello, Samuel N Friedman, et al.
The American Journal of Gastroenterology|March 23, 2016
Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective StudyRohit Loomba, Jeffrey Cui, Tanya Wolfson, et al.
Cell Metabolism|July 2, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
JAMA Oncology|January 18, 2019
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology PracticesScott D Ramsey, Joseph M Unger, Laurence H Baker, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Pageof 64

Showing results (491-500 of 636) with videos related to

Sort By:
Pageof 64
Gastroenterology|June 19, 2017
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic SteatohepatitisMichael S Middleton, Elhamy R Heba, Catherine A Hooker, et al.
The New England Journal of Medicine|June 25, 2023
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASHRohit Loomba, Arun J Sanyal, Kris V Kowdley, et al.
Hepatology (Baltimore, Md.)|March 13, 2019
Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance ElastographyCyrielle Caussy, Meera Bhargava, Ida F Villesen, et al.
Contemporary Clinical Trials|March 3, 2021
The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosisManal F Abdelmalek, Edgar D Charles, Arun J Sanyal, et al.
Journal of Hepatology|August 16, 2022
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLDBeom Kyung Kim, Nobuharu Tamaki, Kento Imajo, et al.
Cell Genomics|December 27, 2021
Machine learning enables new insights into genetic contributions to liver fat accumulationMary E Haas, James P Pirruccello, Samuel N Friedman, et al.
The American Journal of Gastroenterology|March 23, 2016
Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective StudyRohit Loomba, Jeffrey Cui, Tanya Wolfson, et al.
Cell Metabolism|July 2, 2020
A Universal Gut-Microbiome-Derived Signature Predicts CirrhosisTae Gyu Oh, Susy M Kim, Cyrielle Caussy, et al.
JAMA Oncology|January 18, 2019
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology PracticesScott D Ramsey, Joseph M Unger, Laurence H Baker, et al.
Alimentary Pharmacology & Therapeutics|March 18, 2022
Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD)Danielle Brandman, Marie Boyle, Stuart McPherson, et al.
Pageof 64